Dublin, April 13, 2026 (GLOBE NEWSWIRE) — The “B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Report 2026” has been added to ResearchAndMarkets.com’s offering. The report provides comprehensive insights on market size, competitive landscape, and opportunities.
The B-cell maturation antigen (BCMA) targeted therapies market is experiencing significant growth, with projections indicating an increase from $15.09 billion in 2025 to $44.29 billion by 2030, at a CAGR of 24%. This growth is driven by rising multiple myeloma cases, advanced BCMA-targeted treatments, and expanding immunotherapy options. Enhanced understanding of BCMA biology and heightened investment in immuno-oncology research are key factors contributing to this upward trend.
Anticipated trends include increased adoption of CAR-T cell therapies, development of bispecific antibody platforms, and greater use of BCMA-targeted antibody-drug conjugates (ADCs). These advancements support the shift towards personalized immunotherapy regimens and improved outcomes for relapsed and refractory myeloma care.
Multiple myeloma, a form of cancer affecting plasma cells, is a primary driver for the demand in BCMA-targeted therapies. Factors such as an aging population, improved diagnostic methods, and healthcare accessibility disparities contribute to rising incidence rates. In 2024, the American Cancer Society projected approximately 35,780 new multiple myeloma cases in the United States alone.
Leading companies like Johnson & Johnson have made significant strides with innovative treatments. In April 2024, Johnson & Johnson’s CARVYKTI (ciltacabtagene autoleucel) received FDA approval, marking a milestone in BCMA-targeted CAR-T cell therapy. Similarly, AstraZeneca’s acquisition of Gracell Biotechnologies for $1.2 billion underscores the ongoing industry consolidation aimed at strengthening cell therapy portfolios.
Key players in the BCMA-targeted therapies market include Bristol Myers Squibb, Novartis, GlaxoSmithKline, and Amgen, among others. These companies are focused on developing CAR-T cell therapy, bispecific antibodies, and ADCs to enhance precision and efficacy in treating multiple myeloma.
The North American region leads the market, with Asia-Pacific, Western and Eastern Europe, and other regions also contributing significantly.
Markets Covered:
- By Product Type: Antibody Drug Conjugates, CAR-T-Cell Therapy, Bispecific Antibodies
- By Indication Type: Multiple Myeloma, Plasma Cell Leukemia
- By End User: Hospitals, Specialty Clinics
Geographic Scope:
- Countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
- Regions: Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Key Attributes
| Report Attribute | Details |
| No. of Pages | 250 |
| Forecast Period | 2026-2030 |
| Estimated Market Value (USD) in 2026 | $18.75 Billion |
| Forecasted Market Value (USD) by 2030 | $44.29 Billion |
| Compound Annual Growth Rate | 24% |
| Regions Covered | Global |
The companies featured in this B-Cell Maturation Antigen (BCMA) Targeted Therapies market report include:
- Bristol Myers Squibb Company
- Novartis
- GlaxoSmithKline
- Takeda Pharmaceutical Company Limited
- Amgen Inc.
- Regeneron Pharmaceuticals
- BeiGene
- Arcellx Inc.
- Poseida Therapeutics
- Legend Biotech Corporation
- Cartesian Therapeutics
- Sutro Biopharma Inc.
- CARsgen Therapeutics
- Precision BioSciences
- Eureka Therapeutics Inc.
- Cellectis
- Allogene Therapeutics
- Affimed
- Bluebird Bio Inc.
- Roche
- Ichnos Sciences
For more information about this report visit https://www.researchandmarkets.com/r/qt10px
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
- B-Cell Maturation Antigen (BCMA) Targeted Therapies Market
